Classification of Non-Small Cell Lung Cancer’s Tumor Immune Micro-Environment and Strategies to Augment Its Response to Immune Checkpoint Blockade

Characterization of the immune landscape of EGFR-mutant NSCLC identifies CD73/adenosine pathway as a potential therapeutic target

(2021) Xiuning Le et al.   Journal of Thoracic Oncology

Tumor β‑catenin expression is associated with immune evasion in non‑small cell lung cancer with high tumor mutation burden

(2021) Satoshi Muto et al.   Oncology Letters

Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer

(2021) Marina Martinez et al.   OncoImmunology

Laminin γ2–mediating T cell exclusion attenuates response to anti–PD-1 therapy

(2021) Lei Li et al.   Science Advances

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

(2020) G.R. Oxnard et al.   ANNALS OF ONCOLOGY

Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients

(2020) Daan P. Hurkmans et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study

(2020) Roy S. Herbst et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced Non Small Cell Lung Cancer with BRAF, HER2 or MET mutation or RET-translocation. GFPC 01-2018.

(2020) Florian Guisier et al.   Journal of Thoracic Oncology

STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype

(2020) Carminia M. Della Corte et al.   Journal of Thoracic Oncology

Comprehensive T cell repertoire characterization of non-small cell lung cancer

(2020) Alexandre Reuben et al.   Nature Communications

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances

(2020) Hanne Lind et al.   Journal for ImmunoTherapy of Cancer

Emerging role of PTEN loss in evasion of the immune response to tumours

(2020) Thiago Vidotto et al.   BRITISH JOURNAL OF CANCER

Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy

(2020) Anna-Larissa Nadia Niemeijer et al.   BRITISH JOURNAL OF CANCER

Selective targeting of different populations of myeloid-derived suppressor cells by histone deacetylase inhibitors

(2020) Ayumi Hashimoto et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Transcriptional Upregulation of NLRC5 by Radiation Drives STING- and Interferon-Independent MHC-I Expression on Cancer Cells and T Cell Cytotoxicity

(2020) Lauren K. Zebertavage et al.   Scientific Reports

IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution

(2020) Erika F. Rodriguez et al.   Cancer Medicine

Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer

(2020) Fan Sun et al.   Journal for ImmunoTherapy of Cancer

Clinical development of therapies targeting TGFβ: current knowledge and future perspectives.

(2020) D. Ciardiello et al.   ANNALS OF ONCOLOGY

The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer

(2020) Adam J Schoenfeld et al.   CLINICAL CANCER RESEARCH

Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer

(2020) Kyoung-Ho Pyo et al.   Journal for ImmunoTherapy of Cancer

KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden

(2020) D. Marinelli et al.   ANNALS OF ONCOLOGY

Turning up the heat on MYC: Progress in small molecule inhibitors

(2020) Mihai I Truica et al.   CANCER RESEARCH

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

(2020) Roy S. Herbst et al.   NEW ENGLAND JOURNAL OF MEDICINE

Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma

(2020) Anusha Kalbasi et al.   Science Translational Medicine

KEAP1/NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition

(2020) Michael S Binkley et al.   Cancer Discovery

Combination of radiotherapy and suppression of Tregs enhances abscopal antitumor effect and inhibits metastasis in rectal cancer

(2020) Dengbo Ji et al.   Journal for ImmunoTherapy of Cancer

Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies

(2020) Julie Preillon et al.   MOLECULAR CANCER THERAPEUTICS

Cytokine and Chemokine Signals of T-Cell Exclusion in Tumors

(2020) Yu Zhang et al.   Frontiers in Immunology

Enhancing anti-tumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors

(2019) K M Heinhuis et al.   ANNALS OF ONCOLOGY

WNT/β-catenin pathway activation correlates with immune exclusion across human cancers

(2019) Jason J. Luke et al.   CLINICAL CANCER RESEARCH

Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1−CD8+ Tumor-Infiltrating T Cells

(2019) Sema Kurtulus et al.   IMMUNITY

Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy

(2019) Imran Siddiqui et al.   IMMUNITY

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

(2019) Martin Reck et al.   Lancet Respiratory Medicine

Immune-Checkpoint Blockade Opposes CD8+ T-cell Suppression in Human and Murine Cancer

(2019) Lukas W. Pfannenstiel et al.   Cancer Immunology Research

Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity

(2019) Masanori Onda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

(2019) Brian C. Miller et al.   NATURE IMMUNOLOGY

Neoantigen-directed immune escape in lung cancer evolution

(2019) Rachel Rosenthal et al.   NATURE

Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)

(2019) Arnaud Jeanson et al.   Journal of Thoracic Oncology

T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy

(2019) Tori N. Yamamoto et al.   JOURNAL OF CLINICAL INVESTIGATION

Severe immune related adverse events are common with sequential PD-(L)1 blockade and osimertinib

(2019) A J Schoenfeld et al.   ANNALS OF ONCOLOGY

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

(2019) J Mazières et al.   ANNALS OF ONCOLOGY

LKB1 and KEAP1/NRF2 pathways cooperatively promote metabolic reprogramming with enhanced glutamine dependence in KRAS-mutant lung adenocarcinoma

(2019) Ana Galan-Cobo et al.   CANCER RESEARCH

Expression analysis and significance of PD-1, LAG-3 and TIM-3 in human non-small cell lung cancer using spatially-resolved and multiparametric single-cell analysis.

(2019) Ila J Datar et al.   CLINICAL CANCER RESEARCH

Transforming Growth Factor-β Signaling in Immunity and Cancer

(2019) Eduard Batlle et al.   IMMUNITY

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

(2019) Tony S K Mok et al.   LANCET

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer

(2019) K Hastings et al.   ANNALS OF ONCOLOGY

Mutations in the KEAP1-NFE2L2 pathway define a molecular subset of rapidly progressing lung adenocarcinoma

(2019) Frauke Goeman et al.   Journal of Thoracic Oncology

Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer

(2019) Willemijn S. M. E. Theelen et al.   PLoS One

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination

(2019) Mathieu Grapin et al.   Journal for ImmunoTherapy of Cancer

An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer

(2019) Marian L. Burr et al.   CANCER CELL

Specific targeting of CD163+ TAMs mobilizes inflammatory monocytes and promotes T cell–mediated tumor regression

(2019) Anders Etzerodt et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3 Knock-In Mice

(2019) Elena Burova et al.   MOLECULAR CANCER THERAPEUTICS

MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers

(2019) Livingstone Fultang et al.   EBioMedicine

Myeloid immunosuppression and immune checkpoints in the tumor microenvironment

(2019) Kyohei Nakamura et al.   Cellular & Molecular Immunology

Immune cell PD-L1 co-localizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy

(2019) Yuting Liu et al.   CLINICAL CANCER RESEARCH

Galectin-1–driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance

(2019) Dhanya K. Nambiar et al.   JOURNAL OF CLINICAL INVESTIGATION

Mutations in the Antioxidant KEAP1/NRF2 Pathway Define an Aggressive Subset of NSCLC Resistant to Conventional Treatments

(2019) Ernest Nadal et al.   Journal of Thoracic Oncology

Cancer-Cell-Intrinsic cGAS Expression Mediates Tumor Immunogenicity

(2019) Linda Schadt et al.   Cell Reports

T Regulatory Cells and Priming the Suppressive Tumor Microenvironment

(2019) Christina M. Paluskievicz et al.   Frontiers in Immunology

Targeting ST2 expressing activated regulatory T cells in Kras-mutant lung cancer

(2019) Byung-Seok Kim et al.   OncoImmunology

BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19high B lymphocytes

(2019) Yu-Li Chen et al.   Journal for ImmunoTherapy of Cancer

The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity

(2019) Chengming Liu et al.   CANCER LETTERS

Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models

(2019) Sarah Greene et al.   CLINICAL CANCER RESEARCH

Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1–Negative Human Lung Cancers

(2018) Haiying Cheng et al.   CLINICAL CANCER RESEARCH

TP53,STK11andEGFRMutations Predict Tumor Immune Profile and the Response to anti-PD-1 in Lung Adenocarcinoma

(2018) Jerome Biton et al.   CLINICAL CANCER RESEARCH

Clinical and Pathological Characteristics ofKEAP1- andNFE2L2-Mutated Non–Small Cell Lung Carcinoma (NSCLC)

(2018) Rieke Frank et al.   CLINICAL CANCER RESEARCH

The Immune Landscape of Cancer

(2018) Vésteinn Thorsson et al.   IMMUNITY

PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression

(2018) Haidong Tang et al.   JOURNAL OF CLINICAL INVESTIGATION

Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

(2018) Hira Rizvi et al.   JOURNAL OF CLINICAL ONCOLOGY

Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment

(2018) Suzanne Ostrand-Rosenberg et al.   JOURNAL OF IMMUNOLOGY

Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade

(2018) Petar Jelinic et al.   JNCI-Journal of the National Cancer Institute

Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)

(2018) David R. Spigel et al.   Journal of Thoracic Oncology

A Phase II Study of Pembrolizumab in EGFR-mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC

(2018) A. Lisberg et al.   Journal of Thoracic Oncology

Nivolumab Plus Erlotinib in Patients With EGFR -Mutant Advanced NSCLC

(2018) Scott Gettinger et al.   Journal of Thoracic Oncology

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

(2018) Daniele V. F. Tauriello et al.   NATURE

A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade

(2018) Daniela S. Thommen et al.   NATURE MEDICINE

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

(2018) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells

(2018) Qi Lai et al.   ONCOGENE

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect

(2018) María E. Rodríguez-Ruiz et al.   TRENDS IN IMMUNOLOGY

Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different

(2018) Chung-Han Lee et al.   TRENDS IN IMMUNOLOGY

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma

(2018) Ferdinandos Skoulidis et al.   Cancer Discovery

Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade

(2018) Petar Jelinic et al.   JNCI-Journal of the National Cancer Institute

Targeting VEGF/VEGFR to Modulate Antitumor Immunity

(2018) Ju Yang et al.   Frontiers in Immunology

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

(2018) Rikke B. Holmgaard et al.   Journal for ImmunoTherapy of Cancer

Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma

(2018) Tammy Linlin Song et al.   BLOOD

Immune marker profiling and PD-L1 expression across Non-Small Cell Lung Cancer mutations

(2018) Maria I. Toki et al.   Journal of Thoracic Oncology

The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression

(2018) Shengxiang Ren et al.   LUNG CANCER

RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade

(2018) Shanthi Ganesh et al.   MOLECULAR THERAPY

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

(2018) Sanjeev Mariathasan et al.   NATURE

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

(2018) David R. Gandara et al.   NATURE MEDICINE

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

(2018) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

(2018) Luis Paz-Ares et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nrf2 negatively regulates STING indicating a link between antiviral sensing and metabolic reprogramming

(2018) David Olagnier et al.   Nature Communications

Radiotherapy induces responses of lung cancer to CTLA-4 blockade

(2018) Silvia C. Formenti et al.   NATURE MEDICINE

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)

(2018) Marcin Kowanetz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer

(2018) Shunsuke Kitajima et al.   Cancer Discovery

VEGF as a potential target in lung cancer

(2017) Daniela Frezzetti et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas

(2017) Gary Kohanbash et al.   JOURNAL OF CLINICAL INVESTIGATION

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

(2017) Mark Ayers et al.   JOURNAL OF CLINICAL INVESTIGATION

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

(2017) Leora Horn et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-1 Axis Inhibition in EGFR Positives: A Blunt Sword?

(2017) David F. Heigener et al.   Journal of Thoracic Oncology

LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes

(2017) Yayi He et al.   Journal of Thoracic Oncology

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

(2017) Fred R. Hirsch et al.   Journal of Thoracic Oncology

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

(2017) David P. Carbone et al.   NEW ENGLAND JOURNAL OF MEDICINE

A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer

(2017) E-J Choi et al.   ONCOGENE

Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation

(2017) Elizabeth Allen et al.   Science Translational Medicine

Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes

(2017) Jingjing Zhu et al.   Nature Communications

DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity

(2017) Claire Vanpouille-Box et al.   Nature Communications

JAK Mutations as Escape Mechanisms to Anti–PD-1 Therapy

(2017) Aurelien Marabelle et al.   Cancer Discovery

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

(2017) Scott Gettinger et al.   Cancer Discovery

Transfer of Allogeneic CD4 + T Cells Rescues CD8 + T Cells in Anti-PD-L1–Resistant Tumors Leading to Tumor Eradication

(2017) Ainhoa Arina et al.   Cancer Immunology Research

Intratumoral CD8 + T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity

(2017) Brendan L. Horton et al.   Cancer Immunology Research

A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells

(2017) Justin M. David et al.   OncoImmunology

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy

(2017) Jan Willem Kleinovink et al.   OncoImmunology

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer

(2017) Zhong-Yi Dong et al.   OncoImmunology

Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)

(2016) J. M. Kim et al.   ANNALS OF ONCOLOGY

STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment

(2016) S. Koyama et al.   CANCER RESEARCH

Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition

(2016) Carolina Pereira et al.   CLINICAL CANCER RESEARCH

Dual Faces of IFN  in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity

(2016) M. Mandai et al.   CLINICAL CANCER RESEARCH

Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer

(2016) Kurt A. Schalper et al.   CLINICAL CANCER RESEARCH

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis

(2016) J. F. Gainor et al.   CLINICAL CANCER RESEARCH

The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration

(2016) Francisco Perea et al.   INTERNATIONAL JOURNAL OF CANCER

Does Heavy Ion Therapy Work Through the Immune System?

(2016) Marco Durante et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

New and emerging targeted treatments in advanced non-small-cell lung cancer

(2016) Fred R Hirsch et al.   LANCET

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

(2016) Louis Fehrenbacher et al.   LANCET

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Clinical Implications of Genomic Discoveries in Lung Cancer

(2016) Charles Swanton et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway

(2016) Vassiliki A. Boussiotis   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

(2016) N. McGranahan et al.   SCIENCE

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

(2016) Shohei Koyama et al.   Nature Communications

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

(2016) P.-L. Chen et al.   Cancer Discovery

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

(2016) Daniel Sanghoon Shin et al.   Cancer Discovery

Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer

(2016) Valsamo Anagnostou et al.   Cancer Discovery

VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma

(2016) X. Wu et al.   Cancer Immunology Research

Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer

(2015) Kristin J. Lastwika et al.   CANCER RESEARCH

Classifying Cancers Based on T-cell Infiltration and PD-L1

(2015) Michele W.L. Teng et al.   CANCER RESEARCH

Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer

(2015) K. Ota et al.   CLINICAL CANCER RESEARCH

VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation

(2015) Hua Huang et al.   FASEB JOURNAL

VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors

(2015) Thibault Voron et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

(2015) Nan Chen et al.   Journal of Thoracic Oncology

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy

(2015) Dongjun Peng et al.   NATURE

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

(2015) Stefani Spranger et al.   NATURE

β-Catenin in dendritic cells exerts opposite functions in cross-priming and maintenance of CD8+T cells through regulation of IL-10

(2015) Chunmei Fu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy

(2015) W. Peng et al.   Cancer Discovery

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

(2015) Leticia Corrales et al.   Cell Reports

Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors

(2015) D. S. Thommen et al.   Cancer Immunology Research

Role of Local Radiation Therapy in Cancer Immunotherapy

(2015) Sandra Demaria et al.   JAMA Oncology

Targeting the indoleamine 2,3-dioxygenase pathway in cancer

(2015) Yong Wha Moon et al.   Journal for ImmunoTherapy of Cancer

The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function

(2014) Robert J. Johnston et al.   CANCER CELL

Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond

(2014) Niki Karachaliou et al.   Expert Review of Anticancer Therapy

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors

(2014) Liufu Deng et al.   IMMUNITY

Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction

(2014) Christian A. Bauer et al.   JOURNAL OF CLINICAL INVESTIGATION

LKB1 Loss Induces Characteristic Patterns of Gene Expression in Human Tumors Associated with NRF2 Activation and Attenuation of PI3K-AKT

(2014) Jacob M. Kaufman et al.   Journal of Thoracic Oncology

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors

(2014) Gregory T Motz et al.   NATURE MEDICINE

Molecular Pathways: Coexpression of Immune Checkpoint Molecules: Signaling Pathways and Implications for Cancer Immunotherapy

(2013) C. J. Nirschl et al.   CLINICAL CANCER RESEARCH

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

(2013) E. A. Akbay et al.   Cancer Discovery

Galectin-1 Promotes Lung Cancer Progression and Chemoresistance by Upregulating p38 MAPK, ERK, and Cyclooxygenase-2

(2012) L.-Y. Chung et al.   CLINICAL CANCER RESEARCH

IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development

(2012) Courtney Smith et al.   Cancer Discovery

Anti-TIM3 Antibody Promotes T Cell IFN- -Mediated Antitumor Immunity and Suppresses Established Tumors

(2011) S. F. Ngiow et al.   CANCER RESEARCH

Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells

(2011) Barbara Molon et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma-Rationale for Comprehensive Mutation Profiling

(2011) J. E. Chaft et al.   MOLECULAR CANCER THERAPEUTICS

TGF-² Signaling Pathway in Lung Adenocarcinoma Invasion

(2010) Rebecca L. Toonkel et al.   Journal of Thoracic Oncology

Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosis

(2010) M Tessema et al.   ONCOGENE

TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression

(2010) Li Yang et al.   TRENDS IN IMMUNOLOGY

Transforming growth factor beta (TGF-β) and inflammation in cancer

(2009) Brian Bierie et al.   CYTOKINE & GROWTH FACTOR REVIEWS